Sansure Biotech

Sansure Biotech Inc. (圣湘生物科技股份有限公司) describes itself as a 'diagnosis-and-treatment integrated' full-scenario solution provider built around proprietary genetic technology, combining reagents, instruments, quality control, third-party medical testing, health consumer products, AI+biopharma and AI+bio-manufacturing. It is listed on the STAR Market under ticker 688289 and states it has been included in China's top 100 pharmaceutical industry and global medical device TOP100 lists. The company says it uses Changsha and Shanghai as dual strategic anchors, with subsidiaries or branches in major Chinese cities such as Beijing, Chengdu and Guangzhou and in international regions including the UK, France, the US, Indonesia, the Philippines and Thailand. It reports developing more than 1,000 products and offering over 2,200 testing services, serving more than 160 countries and regions.

Sansure Biotech Inc. states that it was established in 2008. It describes itself as a 'diagnosis-and-treatment integrated' full-scenario solution provider centered on proprietary genetic technology, integrating reagents, instruments, quality control, third-party medical testing, health consumer products, AI+biopharma and AI+bio-manufacturing. The company is listed on the STAR Market under ticker 688289 and states it has been included in China's top 100 pharmaceutical industry and global medical device TOP100 lists. It says it uses Changsha and Shanghai as dual strategic anchors, radiating nationwide and globally, with subsidiaries or branches in major Chinese cities such as Beijing, Chengdu and Guangzhou and in international regions including the UK, France, the US, Indonesia, the Philippines and Thailand. The company reports developing more than 1,000 products and offering over 2,200 testing services, with products and solutions serving more than 160 countries and regions and cumulative testing products provided to nearly 4 billion person-times. It also states it has donated nearly 500 million yuan in cash and materials in public health events, livelihood projects, rural revitalization and disaster relief.

• 2026

  On April 7, 2026, Sansure Biotech announced that Academician Dai Hongjie joined the company, together with the Hunan Jinfurong Sansure Biotech Equity Investment Fund Partnership (Limited Partnership).

• 2026

  On August 17, 2026, Sansure Biotech's self-developed dengue virus and chikungunya virus nucleic acid detection kit (PCR-fluorescence probe method) received medical device registration approval from the National Medical Products Administration.

• 2026

  In August 2026, five Sansure Biotech nucleic acid detection products received CE IVDR certification, covering respiratory, cervical cancer, and blood-borne infection areas.

• 2026

  In July 2026, Sansure Biotech's lyophilized quadruple test kit for SARS-CoV-2, influenza A, influenza B, and RSV received marketing approval.

• 2026

  On September 20–21, 2026, Sansure Biotech held its 2026 National Core Channel Strategic Summit in Shanghai with more than 120 core channel partners.

• 2025

  On November 25, 2025, Alibaba Health and Sansure Biotech signed a strategic cooperation agreement focused on respiratory infectious diseases and at-home testing.

• 2020

  Sansure Biotech is listed on China's STAR Market under stock code 688289.

• 2008

  Sansure Biotech was founded; the company's official profile lists 2008 as its founding year.

Diagnosis-and-treatment integrated full-scenario solution provider; stated ambition to become a world-class enterprise and a world-class solution provider in infectious diseases.

• Reagents

• Instruments

• Gene testing services

• Comprehensive solutions

• Research services

• Independent clinical laboratory services

• 2022

  Then-director Zhu Jinwei of Sansure Biotech warned by Hunan regulator for selling shares below issue price

  Zhu Jinwei, then a director of Sansure Biotech and a shareholder holding more than 5%, sold shares at a price below the issue price, breaching his commitment and failing to first return the proceeds from the违规 share reduction; he received a warning letter from the Hunan Securities Regulatory Bureau. Status: regulatory measure. Entities involved: Sansure Biotech Co., Ltd. and Zhu Jinwei. Scope: shareholder share reduction.

  Source

Read more

• 2020.07.30

  Reported2020.08.01

  Shengxiang Bio launches iPonatic rapid nucleic acid testing system[8]圣湘生物发布iPonatic快速核酸检测系统hunan.voc.com.cn

  Shengxiang Bio launched its iPonatic rapid nucleic acid testing system on July 30. The system combines nucleic acid testing reagents and an analyzer and can produce COVID-19 test results in 15 to 45 minutes.

Read more

1. 1圣湘生物 （688289）— 生命科技人人可及sansure.com.cn
2. 2圣湘生物 （688289）— 生命科技人人可及sansure.com.cn
3. 3圣湘生物 （688289）— 生命科技人人可及sansure.com.cn
4. 4圣湘生物 （688289）— 生命科技人人可及sansure.com.cn
5. 5Sansure Biotech (China)wikidata.org
6. 6Then-director Zhu Jinwei of Sansure Biotech warned by Hunan regulator for selling shares below issue priceepaper.cs.com.cn
7. 7Then-director Zhu Jinwei of Sansure Biotech warned by Hunan regulator for selling shares below issue priceepaper.zqrb.cn
8. 8圣湘生物发布iPonatic快速核酸检测系统hunan.voc.com.cn